The National Cancer Institute (NCI), plans to procure services and supplies on a sole source basis for services regarding: Searching for P53 mutation signatures of PAH exposure in esophageal tissues with the International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, 69372 Lyon Cedex 09, France. The supplies and services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106. The North American Industry Classification System Code is 621511 and the business size standard is $12.5M. The purpose of this procurement, for the proposed study, is to search for P53 mutation signatures of PAH exposure in tumor and non-neoplastic esophageal tissues from ESCC cases and non-neoplastic esophageal tissues from controls, and to evaluate the association between these signatures and case status. The case and control subjects in this study shall be from Golestan Province, which is the high-risk area of Iran for ESCC. IARC is the only major research institution conducting a case-control study of esophageal cancer at the western end of the Central Asian Esophageal Cancer Belt, and is therefore the only known source for data and biological samples from this area. IARC has a long history of quality research activities, including research in this geographic area of Iran. The comparison of results from this and other high risk areas, which are very different geographically, culturally and ethnically, will be a valuable resource for identifying etiologic risk factors for this disease that are important throughout the world. The contractor shall: 1) Stain tumor microarrays (TMAs) made from esophageal tumors and non-neoplastic esophageal tissue for PAH-DNA adducts using the 5D11 antibody; 2) Stain the same TMAs for p53 protein expression using a panel of four antibodies (DO7, PAb1801, CM1, and anti-phospho15); 3) Sequence the P53 gene in adduct-positive and adduct-negative tissues from ESCC case and control subjects and; 4) Examine the association between P53 gene mutations, p53 protein expression, the presence of PAH-DNA adducts, and case status. The contractor shall do the above-mentioned analyses on four alcohol-fixed microarrays obtained from ESCC cases and matched controls enrolled in the case-control study recently conducted in the high-risk areas of northeastern Iran. Contractor shall prepare a report and submit to the NCI project officer at the end of the period of performance. The Period of Performance shall be for six (6) months from date of award. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow the researcher to determine if the party can perform this requirement. An original and one copy of the capability statement must be received in the contracting office by 11:00 am ET on March 11, 2008 to Malinda Holdcraft, Contract Specialist. All questions must be in writing and can be faxed to 301-402-4513 or sent via email to [email protected]. It is the vendors? responsibility to call 301-402-4509 or email the aforementioned individual to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certifications in the Central Contractor Registration (CCR), http://www.ccr.gov and the Online Representations and Certifications Applications (ORCA) http://orca.bpn.gov. Please reference NCI-80041-NG on all correspondence.

Bid Protests Not Available